Post Tagged with: "sativex"

This Medical Pot Penny Stock Is Not What You Think It Should Be

This Medical Pot Penny Stock Is Not What You Think It Should Be

Shipments of Acorda Therapeutics’ (NASDAQ: ACOR) spasticity treatment Zanaflex reached $60 million in 2011 before the drug hit generic competition. That’s nothing to get too excited about, especially since Sativex will probably only be used in patients where generic Zanaflex isn’t working. In the U.S., GW Pharmaceuticals isn’t even prioritizing approval for multiple sclerosis spasticity. Its lead indication is in […]

June 18, 2014 · 0 comments · Feature Article
This Medical Pot Penny Stock Is Not What You Think It Is

This Medical Pot Penny Stock Is Not What You Think It Is

Otsuka Pharmaceutical testing Sativex in cancer pain will read out toward the end of this year. It’s potentially a larger market — sales of Teva’s pain medication Actiq peaked at more than $600 million — but the sales potential will depend on how well Sativex reduces pain, its side effects, and the potential for abuse. There are quite a few […]

June 18, 2014 · 0 comments · Feature Article
Marijuana Wars: GW Pharmaceuticals Vs. Medbox Showdown

Marijuana Wars: GW Pharmaceuticals Vs. Medbox Showdown

That being said, I think GW Pharmaceuticals is perhaps one of the few “marijuana stocks” worth considering as a long-term investment. The company has an intriguing platform that has been validated by the approval of Sativex as a treatment for multiple sclerosis spasticity and has incoming revenue from sales of the drug. Even so, GW’s current valuation doesn’t look cheap […]

May 21, 2014 · 0 comments · Feature Article
Cramer Turns To Cannabis Seeking New High

Cramer Turns To Cannabis Seeking New High

And that’s GW Pharmaceuticals…In fact, Cramer’s so enthusiastic, he made this stock his pick for ‘Spec Friday,’ a regular “Mad Money” feature in which Cramer presents a more speculative opportunity that presents higher risk but also higher reward. In the case of GW Pharma, Cramer says buying the stock is a bullish bet on the company’s ability to extract various […]

May 5, 2014 · 0 comments · Feature Article
This Medical Marijuana Stock Is Not What You Think It Is

This Medical Marijuana Stock Is Not What You Think It Is

GW Pharmaceuticals is staying well within the federal laws with plans to seek approval by the Food and Drug Administration to sell its marijuana-derived prescription drugs. Which explains why GW Pharmaceuticals is a $685 million company while most of the medical marijuana companies are penny stocks. A different kind of risk GW Pharmaceuticals doesn’t have to deal with legal uncertainty, […]

April 29, 2014 · 0 comments · Feature Article
GW Pharmaceuticals  Is The Most Legit When It Comes To Marijuana Stocks

GW Pharmaceuticals Is The Most Legit When It Comes To Marijuana Stocks

Of course, that doesn’t mean I would recommend buying GW Pharmaceuticals; being a legitimate business doesn’t guarantee you success and even if it did, success doesn’t guarantee the stock will go up. GWPH stock has exploded in the last year, up about eightfold from spring 2013. But, unfortunately, its valuation is based more on hope than anything since the company […]

April 25, 2014 · 0 comments · Feature Article
PLEASE SUBSCRIBE
Get the latest content first.
©Marijuana Stocks Report